|
|
|
市場調査レポート
癌ワクチン：市場予測・創薬およびパイプライン分析
Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition
|
Abstract
It is the general consensus of scientists that cancer vaccines will become a
reality. Overall the cancer treatment market continues to grow and this demand
sets the stage for vaccine products.
Several promising vaccines: the propholactic Gardasil has created a pathway
for new vaccine products. M-Vax, Ocon-Vax in late stage development and are
preparing for regulatory review in the United States, Europe, Canada, or other
international regions. Many of the products with potential approval status
over the coming years are already in Phase III development, have orphan drug
status, SPA status, or Fast Track status. This provides a promising future for
many of these products. Additionally, some products in international regions
have been granted compassionate use status which is significant in evaluating
need on a patient-by-patient basis. In this report, Kalorama Information
provides a realistic estimate of the cancer vaccine for the near term for the
following products:
- Melonoma Vaccines
- Lung Cancer Vaccines
- Prostate Cancer Vaccines
- Cervical Cancer Vaccines
- Brain Cancer Vaccines
- Colon/Rectal Cancer Vaccines
- Breast Cancer Vaccines
- Lymphoma Vaccines
- Ovarian Cancer Vaccines
- Leukemia Vaccines
- Bladder Cancer Vaccines
As part of its exhaustive research and analysis, this report provides:
- Forecasts for Future Revenues from Cancer Vaccines
- Cancer Epidemiology
- Reviews of Products in the Pipeline
- Detailed Profiles of 13 Companies Operating in the Cancer Vaccine Market
- Directory of Related Companies
Some of the issues discussed in this report important for anyone operating in this market include:
- Introduction
- Early Detection and Screening
- Monoclonal Antibodies and Therapeutic Vaccines
- Political and Social Pressure
- Insurance and Reimbursement Issues
- Personalized Medicine
- Pharmacogenomics
- Vaccine Strategies
- New Genetic Technique
- Future Growth in Vaccines
As part of its detailed coverage of developments in cancer vaccines..the following companies are profiled in this report:
- Antigenics, Inc.
- Avax Technologies, Inc.
- Biovest International, Inc.
- Cell Genesys, Inc.
- Dendreon Corporation
- Genitope Corporation
- GlaxoSmithKline plc
- Merck & Company, Inc.
- Northwest Biotherapeutics, Inc.
- NovaRx
- Oncothyreon
- Vaccinogen
- Vical, Inc.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
CHAPTER TWO: INTRODUCTION
- Introduction
- History and Growth of the Cancer Treatment Market
- Types of Vaccines
- Antigen/Adjuvant Vaccines
- Whole Cell Tumor Vaccines
- Dendritic Cell (DC) Vaccines
- Viral Vectors and DNA Vaccines
- Idiotype Vaccines
- Types of Therapeutic Vaccines
- Patient-Specific Vaccines
- Prostate Specific Antigen
- Sialyl Tn
- Heat Shock Proteins
- Ganglioside Molecules
- Carcinoembryonic Antigen (CEA)
- MART-1
- Tyrosinase
- Adjuvants
- Industry Structure
- Demographics and Statistics
- Growing and Aging Population
- Life Expectancy and Cancer
CHAPTER THREE: CERVICAL CANCER VACCINES
- Overview
- Description of Vaccines on the Market
- Gardasil/Silgard
- Cervarix
- Description of Vaccines in Development
- TG 4001/R3484
- HspE7
- Lovaxin C
- VGX-3100
- CA-9
- Market Summary
- Current and Potential Competitors and Analysis, 2012
CHAPTER FOUR: COLON/RECTAL CANCER VACCINES
- Overview
- Description of Vaccines on the Market
- Description of Vaccines in Development
- OncoVAX
- TroVAX
- Avicine
- CEA VRP Vaccine
- Collidem
- IMA910
- Lapuleucel-T
- Oncophage
- CDX-1307-01
- Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
- MKC1106-PP
- Market Summary
- Potential Competitors and Analysis, 2012
CHAPTER FIVE: LUNG CANCER VACCINES
- Overview
- Description of Vaccines in Development
- Lucanix
- MAGE-A3 Peptide
- Stimuvax
- EGF Cancer Vaccine
- GV-1001
- HyperAcute Lung
- IDM 2101 (EP-2101)
- Oncophage
- INGN 225
- TG 4010
- LungVAX
- Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
- DC Vax
- L523S
- Market Summary
- Potential Competitors and Analysis, 2012
CHAPTER SIX: LYMPHOMA VACCINES
- Overview
- Description of Vaccines in Development
- MyVax
- BiovaxID
- FavId
- TG 1042
- Market Summary
- Potential Competitors and Analysis, 2012
CHAPTER SEVEN: MELANOMA VACCINES
- Overview
- Description of Vaccines on the Market
- Description of Vaccines in Development
- M-VAX
- GMK
- Allovectin-7
- MDX-1379 with Combination Treatment MDX-010
- Oncophage
- MAGE-A3 ASCI 3
- Uvidem
- AGI-101H Vaccine
- ALVAC Vaccine
- HyperAcute Melanoma
- Market Summary
- Potential Competitors and Analysis, 2012
CHAPTER EIGHT: PROSTATE CANCER VACCINES
- Overview
- Description of Vaccines in Development
- Provenge
- DCVax-Prostate
- GVAX
- ProstAtak
- TroVAX
- Telomerase Cancer Vaccine
- MVA-BN Prostate
- HyperAcute Prostate
- MKC1106-PP
- Market Summary
- Potential Competitors and Analysis, 2012
CHAPTER NINE: BREAST CANCER VACCINES
- Overview
- Description of Vaccines in Development
- INGN 225
- CEA VRP Vaccine
- MVA-BN HER2
- Lapuleucel-T
- PX 104.1
- CDX-1307-02
- Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
- MKC1106-PP
- Market Summary
CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES
- Overview
- Description of Vaccines in Development
- GV 1001
- GI-4000
- Avicine
- GVAX
- HyperAcute Pancreas
- Oncophage
- CDX-1307-01
- CRS-100
- CRS-207
- DC Vax
- MKC1106-PP
- Market Summary
CHAPTER ELEVEN: RENAL CANCER VACCINES
- Overview
- Description of Vaccines on the Market
- Description of Vaccines in Development
- Oncophage
- Reniale
- TroVAX
- IMA901
- AGS-003
- MDX-1106
- MKC1106-PP
- Market Summary
- Potential Competitors and Analysis, 2012
CHAPTER TWELVE: BRAIN CANCER VACCINES
- Overview
- Glioblastoma
- Neuroblastoma
- Description of Vaccines in Development
- DCVax-Brain
- CDX-110
- GliAtak
- Oncophage
- Market Summary
CHAPTER THIRTEEN: BLADDER CANCER VACCINES
- Overview
- Description of Vaccines on the Market
- BCG Therapy (OncoTICE- Organon Teknika) (Immucyst-Sanofi
Pasteur)(Pacis-Shire Pharmaceuticals)
- Description of Vaccines in Development
- Bexidem
- CG0070
- MDX-1307-01
- Market Summary
CHAPTER FOURTEEN: OVARIAN CANCER VACCINES
- Overview
- Description of Vaccines in Development
- OVax Autologous Cell Vaccine
- Lapuleucel-T
- Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
- MKC1106-PP
- Market Summary
CHAPTER FIFTEEN: LEUKEMIA VACCINES
- Overview
- Description of Vaccines in Development
- GVAX
- PR1 Peptide Vaccine
- AGS-005
- Market Summary
CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
- Introduction
- Early Detection and Screening
- Monoclonal Antibodies and Therapeutic Vaccines
- Political and Social Pressure
- Insurance and Reimbursement Issues
- Personalized Medicine
- Pharmacogenomics
- Vaccine Strategies
- New Genetic Technique
- Future Growth in Vaccines
CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS
- Overview
- Total Market Size and Forecast
- Market and Competitor Analysis
CHAPTER EIGHTEEN: CANCER VACCINE CORPORATE PROFILES
- Introduction
- Antigenics, Inc
- Avax Technologies, Inc
- Biovest International, Inc
- Cell Genesys, Inc
- Dendreon Corporation
- Genitope Corporation
- GlaxoSmithKline plc
- Merck & Company, Inc
- Northwest Biotherapeutics, Inc
- NovaRx
- Oncothyreon
- Vaccinogen
- Vical, Inc
CHAPTER NINETEEN: COMPANY NAMES AND ADDRESSES
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine
Markets, 2008-2012
- Figure 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine
Markets, 2008-2012
CHAPTER TWO: INTRODUCTION
- Table 2-1: Estimated and Projected World Cancer Incidence by Selected
Types of Cancer, 2007 and 2020
- Figure 2-1: Estimated and Projected World Cancer Incidence by Selected
Types of Cancer, 2007 and 2020
- Table 2-2: Total Cancer Incidence by Sex and Country, 2007 Estimates
- Figure 2-2: Total Cancer Incidence by Sex and Country
- Table 2-3: World Population by Selected Geographical Region, 2007-2050
- Figure 2-4: World Population by Selected Geographical Region, 2007-2050
- Table 2-4: Estimated World Population by Age and Geographical Region, 2007
- Figure 2-4: Estimated World Population by Age and Geographical Region, 2007
- Table 2-5: Percent Population Over 65 by Year and Region
- Figure 2-5: Estimated World Population by Age, 2007 and 2050
- Table 2-6: Life Expectancy at Birth by Selected Countries, 2006
- Table 2-6: United States Average Years of Life Lost Per Person Dying of
Cancer, All Races, Both Sexes, 2004
- Table 2-7: United States Estimated Person-Years of Life Lost Due to
Cancer, All Races, Both Sexes, 2004
CHAPTER THREE: CERVICAL CANCER VACCINES
- Table 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007
- Figure 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007
- Table 3-2: Cervical Cancer Vaccines Approved and in the Pipeline
- Table 3-3: The Developing Cervical Cancer Vaccine Market, 2008-2012
- Figure 3-2: The Developing Cervical Cancer Vaccine Market, 2008-2012
- Table 3-4: The Developing Cervical Cancer Vaccine Market, Leading
Suppliers Shares by Market Revenues, Projected 2012
- Figure 3-3: The Developing Cervical Cancer Vaccine Market, Leading
Suppliers Shares by Market Revenues, Projected 2012
- Figure 3-4: Anticipated Product Sales by Year for Cervical Cancer
Vaccines, 2008-2012
CHAPTER FOUR: COLON/RECTAL CANCER VACCINES
- Table 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country,
2007
- Figure 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country,
2007
- Table 4-2: Colon/Rectal Cancer Vaccines in the Pipeline
- Table 4-3: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012
- Figure 4-2: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012
- Figure 4-3: Anticipated Product Sales by Year for Emerging Colon/Rectal
Cancer Vaccines, 2008-2012
CHAPTER FIVE: LUNG CANCER VACCINES
- Table 5-1: Types of Primary Lung Cancer
- Table 5-2: Estimated World Incidence of Lung Cancer by Country, 2007
- Figure 5-1: Estimated World Incidence of Lung Cancer by Country, 2007
- Table 5-3: Lung Cancer Vaccines in the Pipeline
CHAPTER SIX: LYMPHOMA VACCINES
- Table 6-1: Classification of Non-Hodgkin' s Lymphomas
- Table 6-2: Estimated World Incidence of Lymphoma by Country, 2007
- Figure 6-1: Estimated World Incidence of Lymphoma by Country, 2007
- Table 6-3: Lymphoma Vaccines in the Pipeline
- Table 6-4: The Emerging Lymphoma Vaccine Market, 2008-2012
- Figure 6-2: The Emerging Lymphoma Vaccine Market, 2008-2012
- Table 6-5: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares
by Market Revenues, Projected 2012
- Figure 6-3: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares
by Market Revenues, Projected 2012
- Figure 6-4: Anticipated Product Sales by Year for Emerging Lymphoma
Vaccines, 2010-2012
CHAPTER SEVEN: MELANOMA VACCINES
- Table 7-1: Malignant Condidtions of the Skin
- Table 7-2: Estimated World Incidence of Melanoma by Country, 2007
- Figure 7-1: Estimated World Incidence of Melanoma by Country, 2007
- Table 7-3: Melanoma Vaccines in the Pipeline
- Table 7-4: The Developing Melanoma Vaccine Market, 2008-2012
- Figure 7-2: The Developing Melanoma Vaccine Market, 2008-2012
- Table 7-5: The Developing Melanoma Vaccine Market, Leading Suppliers
Shares by Market Revenues, Projected 2012
- Figure 7-3: The Developing Melanoma Vaccine Market, Leading Suppliers
Shares by Market Revenues, Projected 2012
- Figure 7-4:Anticipated Product Sales by Year for Developing Melanoma
Vaccines, 2010-2012
CHAPTER EIGHT: PROSTATE CANCER VACCINES
- Table 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007
- Figure 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007
- Table 8-2: Prostate Cancer Vaccines in the Pipeline
- Table 8-3: The Emerging Prostate Cancer Vaccine Market, 2008-2012
- Figure 8-2: The Emerging Prostate Cancer Vaccine Market, 2008-2012
- Table 8-4: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers
Shares by Market Revenues, Projected 2012
- Figure 8-3: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers
Shares by Market Revenues, Projected 2012
- Figure 8-4: Anticipated Product Sales by Year for Emerging Prostate
Vaccines, 2010-2012
CHAPTER NINE: BREAST CANCER VACCINES
- Table 9-1: Estimated World Incidence of Breast Cancer by Country, 2007
- Figure 9-1: Estimated World Incidence of Breast Cancer by Country, 2007
- Table 9-2: Breast Cancer Vaccines in the Pipeline
CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES
- Table 10-1: Estimated World Incidence of Gastrointestinal Cancer by
Country, 2007
- Figure 10-1: Estimated World Incidence of Gastrointestinal Cancer by
Country, 2007
- Table 10-2: Gastrointestinal Cancer Vaccines in the Pipeline
CHAPTER ELEVEN: RENAL CANCER VACCINES
- Table 11-1: Estimated World Incidence of Renal Cancer by Country, 2007
- Figure 11-1: Estimated World Incidence of Renal Cancer by Country, 2007
- Table 11-2: Renal Cancer Vaccines in the Pipeline
- Table 11-3: The Developing Renal Cancer Vaccine Market, 2008-2012
- Figure 11-2: The Developing Renal Cancer Vaccine Market, 2008-2012
- Table 11-4: The Developing Renal Cancer Vaccine Market, Leading Suppliers
Shares by Market Revenues, Projected 2012
- Figure 11-3: The Developing Renal Cancer Vaccine Market, Leading Suppliers
Shares by Market Revenues, Projected 2012
- Figure 11-4: Anticipated Product Sales by Year for Renal Cancer Vaccines,
2008-2012
CHAPTER TWELVE: BRAIN CANCER VACCINES
- Table 12-1: Estimated World Incidence of Brain Cancer by Country, 2007
- Figure 12-1: Estimated World Incidence of Brain Cancer by Country, 2007
- Table 12-2: Brain Cancer Vaccines in the Pipeline
CHAPTER THIRTEEN: BLADDER CANCER VACCINES
- Table 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007
- Figure 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007
- Table 13-2: Bladder Cancer Vaccines in the Pipeline
CHAPTER FOURTEEN: OVARIAN CANCER VACCINES
- Table 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007
- Figure 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007
- Table 14-2: Ovarian Cancer Vaccines in the Pipeline
CHAPTER FIFETEEN: LEUKEMIA VACCINES
- Table 15-1: TYPES OF LEUKEMIA
- Table 15-2: Estimated World Incidence of Leukemia by Country, 2007
- Figure 15-1: Estimated World Incidence of Leukemia Cancer by Country, 2007
- Table 15-3: Leukemia Vaccines in the Pipeline
CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
- Table 16-1: Cancer Detection Tests
CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS
- Table 17-1: Cancer Vaccines: Developing and Emerging Cancer
VaccineMarkets, 2008-2012
- Figure 17-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine
Markets, 2008-2012
- Figure 17-2: Cancer Vaccines: Developing and Emerging Cancer Vaccine
Markets by Percent and Vaccine Indication, 2012
CANCER VACCINE CORPORATE PROFILES
COMPANY NAMES AND ADDRESSES
|
 |
